Long-Term Administration of Rho-Kinase Inhibitor Ameliorates Renal Damage in Malignant Hypertensive Rats

  • Yayoi Ishikawa
    From the Department of Hypertension and Cardiorenal Medicine (Y.I., T.N., K.I., H.O., H.M.) and Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Mibu, Tochigi, Japan.
  • Toshio Nishikimi
    From the Department of Hypertension and Cardiorenal Medicine (Y.I., T.N., K.I., H.O., H.M.) and Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Mibu, Tochigi, Japan.
  • Kazumi Akimoto
    From the Department of Hypertension and Cardiorenal Medicine (Y.I., T.N., K.I., H.O., H.M.) and Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Mibu, Tochigi, Japan.
  • Kimihiko Ishimura
    From the Department of Hypertension and Cardiorenal Medicine (Y.I., T.N., K.I., H.O., H.M.) and Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Mibu, Tochigi, Japan.
  • Hidehiko Ono
    From the Department of Hypertension and Cardiorenal Medicine (Y.I., T.N., K.I., H.O., H.M.) and Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Mibu, Tochigi, Japan.
  • Hiroaki Matsuoka
    From the Department of Hypertension and Cardiorenal Medicine (Y.I., T.N., K.I., H.O., H.M.) and Laboratory of Molecular and Cellular Biology (K.A.), Dokkyo University School of Medicine, Mibu, Tochigi, Japan.

抄録

<jats:p>We have shown recently that fasudil, a Rho-kinase inhibitor, has renoprotective effects in salt-sensitive hypertensive rats. We hypothesized that activation of Rho-kinase is involved in the pathogenesis of glomerulosclerosis in malignant hypertensive rats. To test this hypothesis, we studied the following 4 groups: control Wistar–Kyoto rats, untreated deoxycorticosterone-acetate salt spontaneously hypertensive rats (DOCA-SHR), low-dose fasudil-treated DOCA-SHR, and high-dose fasudil-treated DOCA-SHR. After 3 weeks of treatment, the effects of fasudil were examined. DOCA-SHR was characterized by increased blood pressure (BP); increased kidney weight; decreased renal function; increased proteinuria; abnormal histological findings; increased monocyte/macrophage infiltration; increased urinary 8-isoprostran levels; increased gene expression of collagen I, collagen III, transforming growth factor-β, and reduced nicotinamide-adenine dinucleotide phosphate oxidase subunits (p40phox, p47phox, and p67phox); and decreased gene expression of endothelial NO synthase (eNOS) in the renal cortex as compared with Wistar–Kyoto rats. Long-term high-dose fasudil treatment significantly improved renal function and histological findings without changing BP, as compared with untreated DOCA-SHR. Interestingly, long-term fasudil treatment significantly decreased monocyte/macrophage infiltration and urinary 8-isoprostran excretion, in association with decreased mRNA levels of transforming growth factor-β, collagen I, collagen III, and NADPH oxidase subunits (p40phox, p47phox, and p67phox), and increased mRNA levels of eNOS in the renal cortex. Long-term low-dose fasudil treatment tended to improve these variables slightly but did not affect most of them significantly. Our results suggest that long-term fasudil treatment provides renoprotective effects independent of BP-lowering activity. These renoprotective effects are associated with inhibition of extracellular matrix gene expression, monocyte/macrophage infiltration, oxidative stress, and upregulation of eNOS gene expression.</jats:p>

収録刊行物

  • Hypertension

    Hypertension 47 (6), 1075-1083, 2006-06

    Ovid Technologies (Wolters Kluwer Health)

被引用文献 (6)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報

問題の指摘

ページトップへ